Iron(III) pyrophosphate
![]() | |
Names | |
---|---|
Other names
Ferric pyrophosphate
| |
Identifiers | |
| |
3D model (JSmol)
|
|
ChEBI | |
ChemSpider | |
DrugBank | |
ECHA InfoCard | 100.030.160 |
EC Number |
|
PubChem CID
|
|
UNII | |
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
Fe4(P2O7)3 | |
Molar mass | 745.224 (anhydrate) 907.348 (nonahydrate) |
Appearance | yellow solid (nonahydrate)[1] |
insoluble | |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
Clinical data | |
---|---|
Trade names | Triferic, Triferic AVNU |
AHFS/Drugs.com | Professional Drug Facts |
License data | |
Routes of administration | Hemodialysis, intravenous (IV), parenteral |
ATC code |
|
Legal status | |
Legal status |
|
Identifiers | |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.030.160 |
Chemical and physical data | |
Formula | C18H24Fe4O42P6 |
Molar mass | 1321.571 g·mol−1 |
Iron(III) pyrophosphate is an inorganic chemical compound with the formula Fe4(P2O7)3.
Medical uses
Ferric pyrophosphate citrate, sold under the brand name Triferic, is an iron replacement product indicated for the replacement of iron to maintain hemoglobin in adults with hemodialysis-dependent chronic kidney disease.[2][3]
The most common adverse reactions include headache, peripheral edema, asthenia, AV fistula thrombosis, urinary tract infection, AV fistula site hemorrhage, pyrexia, fatigue, procedural hypotension, muscle spasms, pain in extremity, back pain, and dyspnea.[2]
Ferric pyrophosphate citrate was approved for medical use in the United States in January 2015.[4]
Ferric pyrophosphate citrate is a mixed-ligand iron complex in which iron (III) is bound to pyrophosphate and citrate.[2]
Synthesis
Anhydrous iron(III) pyrophosphate can be prepared by heating the mixture of iron(III) metaphosphate and iron(III) phosphate under oxygen with the stoichiometric ratio 1:3. The reactants can be prepared by reacting iron(III) nitrate nonahydrate with phosphoric acid.[5]
It can be also prepared via the following reaction:[6]
- 3 Na4P2O7(aq) + 4 FeCl3(aq) → Fe4(P2O7)3(s) + 12 NaCl(aq)
References
- ^ W.M.Haynes. CRC Handbook of Chemistry and Physics (97th edition). New York: CRC Press, 2016. pp 4-68
- ^ a b c "Triferic- ferric pyrophosphate solution Triferic- ferric pyrophosphate citrate powder Triferic- ferric pyrophosphate citrate solution". DailyMed. 1 November 2019. Retrieved 30 April 2020.
- ^ "Triferic AVNU- ferric pyrophosphate citrate solution". DailyMed. 6 April 2020. Retrieved 30 April 2020.
- ^ "Triferic (ferric pyrophosphate citrate) solution". U.S. Food and Drug Administration (FDA). 2 March 2016. Retrieved 30 April 2020.
- ^ Elbouaanani, L.K; Malaman, B; Gérardin, R; Ijjaali, M (2002). "Crystal Structure Refinement and Magnetic Properties of Fe4(P2O7)3 Studied by Neutron Diffraction and Mössbauer Techniques". Journal of Solid State Chemistry. 163 (2). Elsevier BV: 412–420. doi:10.1006/jssc.2001.9415. ISSN 0022-4596.
- ^ Rossi L, Velikov KP, Philipse AP (May 2014). "Colloidal iron(III) pyrophosphate particles". Food Chem. 151: 243–7. doi:10.1016/j.foodchem.2013.11.050. PMID 24423528.
External links
- "Ferric pyrophosphate". Drug Information Portal. U.S. National Library of Medicine.
- "Ferric pyrophosphate citrate". Drug Information Portal. U.S. National Library of Medicine.